All In Biotech

Drug Trial Radar · NCT02563548

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

56

Actual

Start

Oct 22, 2015

Primary completion

Mar 26, 2019

Study completion Mar 26, 2019

Sponsor

Lead sponsor
Halozyme TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).

Conditions

  • NSCLC
  • Gastric Cancer

Interventions

  • PEGPH20Drug

    PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.

  • PembrolizumabDrug

    Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Escalation Phase: Number of Participants With Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (21 days)
  2. Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With PembrolizumabTime frame: Cycle 1 (21 days)
  3. Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of PEGPH20 in Combination With PembrolizumabTime frame: Cycle 1 (21 days)
  4. Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Cycle 1 Day 1 of dose-expansion phase until death, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks for GAC, and 46 weeks for NSCLC)

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic, Scottsdale, Arizona

    Scottsdale, Arizona

  • California Cancer Associates for Research and Excellence - Encinitas

    Encinitas, California

  • University of California San Diego - Moores Cancer Center

    La Jolla, California

  • St. Joseph's Hospital

    Orange, California

  • University of California - Davis

    Sacramento, California

  • St. Joseph's Hospital

    Santa Rosa, California

  • Innovative Clinical Research

    Whittier, California

  • University of Colorado Denver University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Holy Cross Hospitals

    Fort Lauderdale, Florida

  • University of Miami/Sylvester Cancer Center

    Miami, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Emory University

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Johns Hopkins Kimmel Cancer Center

    Baltimore, Maryland

  • Barbara Ann Karmanos Cancer Center

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • New Jersey Hematology Oncology Associates

    Brick, New Jersey

  • University of Rochester

    Rochester, New York

  • Gabrail Cancer Center

    Canton, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Swedish Health Services

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.